Skip to main content
Clinical Trials/NCT02369887
NCT02369887CompletedNot Applicable

Bureau AIDS, TB, and STI, Thailand Ministry of Public Health

Thai Red Cross AIDS Research Centre1 site in 1 country2,000 target enrollmentStarted: September 15, 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
2,000
Locations
1
Primary Endpoint
Pre-Exposure Prophylaxis of HIV

Study Overview

Brief Summary

This is a prospective observational cohort study that aims to enroll a total of 2000 Thai MSM and TG at five health facilities in four provinces of Thailand. Each participant will be followed for 18 months. Baseline and historical rates of HIV testing/re-testing, initial CD4 counts, retention in care, and ART adherence at the study clinics, at the study clinics combined, and national data (if available) will be compared with rates after implementation of the Test and Treat strategy. Analysis will also include an assessment of HIV prevalence and incidence. This study will use similar objectives, indicators, and procedures as those used in an ongoing Test and Treat study by the Thai Red Cross AIDS Research Centre in three tertiary care hospitals, and a study to be conducted with PEPFAR Key Populations Implementation Science (KPIS) funding through United States Agency for International Development (USAID), in community-based centers, allowing comparison of uptake and follow-up of MSM and TG using the Test and Treat strategy in a variety of settings.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Thai national
  • Age >18 year
  • Male or transgender women who reports anal intercourse with a man without using a condom at least one time in the past 6 months
  • Not known to be HIV-infected
  • Able to read and write Thai
  • Additional inclusion criteria for PrEP:
  • A negative HIV test result
  • No signs or symptoms of acute HIV infection (fever, sore throat, fatigue, rash, swollen glands, nausea, diarrhea, white spots in the mouth) during the previous month
  • Creatinine clearance >60 ml/min
  • No contraindication to PrEP medication

Exclusion Criteria

  • Participating in community-based Test and Treat study

Outcomes

Primary Outcomes

Pre-Exposure Prophylaxis of HIV

Time Frame: 36 months

Participants must be Thai MSM or TG, aged 18 years or older, who report unprotected anal sex with a man during the previous 6 months, can read and write Thai, and are not known to be HIV-infected. To receive PrEP, participants must have a negative HIV test result, no signs or symptoms of acute HIV infection during the previous month, a creatinine clearance result \> 60 ml/min, and no contraindication to PrEP medication.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials